A detailed history of Entry Point Capital, LLC transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Entry Point Capital, LLC holds 6,386 shares of COLL stock, worth $196,624. This represents 0.14% of its overall portfolio holdings.

Number of Shares
6,386
Previous 2,675 138.73%
Holding current value
$196,624
Previous $86.1 Million 99.71%
% of portfolio
0.14%
Previous 0.13%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$31.4 - $39.07 $116,525 - $144,988
3,711 Added 138.73%
6,386 $246,000
Q2 2024

Aug 13, 2024

BUY
$31.36 - $39.99 $13,641 - $17,395
435 Added 19.42%
2,675 $86.1 Million
Q1 2024

May 14, 2024

SELL
$31.23 - $40.91 $30,418 - $39,846
-974 Reduced 30.3%
2,240 $87 Million
Q4 2023

Feb 14, 2024

BUY
$21.16 - $30.8 $68,008 - $98,991
3,214 New
3,214 $98.9 Million

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.05B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Entry Point Capital, LLC Portfolio

Follow Entry Point Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entry Point Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Entry Point Capital, LLC with notifications on news.